Free tool
FAERS Monitor: Forfivo Xl
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022497 or its brand name (Forfivo Xl, Bupropion Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
17,189
Serious
10,285
60% of reports
Hospitalization
4,314
Death reported
1,996
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,998
- headache1,498
- fatigue1,404
- depression1,350
- nausea1,207
- off label use1,072
- pain988
- intentional overdose897
- anxiety886
- drug interaction864
- rash849
- toxicity to various agents823
- completed suicide787
- dizziness768
- overdose741
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 183 |
| 2005 | 196 |
| 2006 | 169 |
| 2007 | 246 |
| 2008 | 317 |
| 2009 | 303 |
| 2010 | 209 |
| 2011 | 387 |
| 2012 | 565 |
| 2013 | 302 |
| 2014 | 323 |
| 2015 | 334 |
| 2016 | 403 |
| 2017 | 659 |
| 2018 | 527 |
| 2019 | 806 |
| 2020 | 776 |
| 2021 | 1,240 |
| 2022 | 1,749 |
| 2023 | 1,733 |
| 2024 | 2,452 |
| 2025 | 1,843 |
| 2026 | 1,467 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,036,970 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| intentional overdoseSignal | 897 | 17.3 | 16.3 | 13,646 |
| completed suicideSignal | 787 | 11.7 | 10.9 | 7,615 |
| depressionSignal | 1,350 | 7.3 | 6.9 | 7,366 |
| drug interactionSignal | 864 | 6.7 | 6.3 | 4,189 |
| toxicity to various agentsSignal | 823 | 6.0 | 5.6 | 3,432 |
| overdoseSignal | 741 | 4.2 | 3.9 | 1,826 |
| anxietySignal | 886 | 3.8 | 3.6 | 1,860 |
| headacheSignal | 1,498 | 2.9 | 2.8 | 1,954 |
| rashSignal | 849 | 2.4 | 2.2 | 695 |
| fatigueSignal | 1,404 | 2.2 | 2.1 | 962 |
| pain | 988 | 2.0 | 1.9 | 484 |
| dizziness | 768 | 1.9 | 1.8 | 326 |
| nausea | 1,207 | 1.9 | 1.8 | 504 |
| drug ineffective | 1,998 | 1.9 | 1.8 | 840 |
| off label use | 1,072 | 1.5 | 1.4 | 185 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.